{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:36:03Z","timestamp":1792035363139,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijid.2026.108826","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:31:31Z","timestamp":1780119091000},"page":"108826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Oral fosfomycin after carbapenems as de-escalating therapy in complicated urinary tract infections: A randomized controlled trial"],"prefix":"10.1016","volume":"170","author":[{"given":"Kirun","family":"Angkanavisan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boonsub","family":"Sakboonyarat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2828-5637","authenticated-orcid":false,"given":"Chutchawan","family":"Ungthammakhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10325","key":"10.1016\/j.ijid.2026.108826_bib0001","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"The lancet"},{"key":"10.1016\/j.ijid.2026.108826_bib0002","unstructured":"Prevention CfDCa. Antibiotic resistance threats in the United States 2019. Available from: https:\/\/www.cdc.gov\/antimicrobial-resistance\/data-research\/threats\/index.html."},{"key":"10.1016\/j.ijid.2026.108826_bib0003","unstructured":"Control ECfDPa. Antimicrobial resistance surveillance in Europe 2023 2021 2023. Available from: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Antimicrobial%20resistance%20surveillance%20in%20Europe%202023%20-%202021%20data.pdf."},{"issue":"2","key":"10.1016\/j.ijid.2026.108826_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jtm\/tav024","article-title":"High carriage rate of ESBL-producing Enterobacteriaceae at presentation and follow-up among travellers with gastrointestinal complaints returning from India and Southeast Asia","volume":"23","author":"Barreto Miranda","year":"2016","journal-title":"J Travel Med"},{"issue":"8","key":"10.1016\/j.ijid.2026.108826_bib0005","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1128\/AAC.00426-09","article-title":"Emergence of high levels of extended-spectrum-\u03b2-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007","volume":"53","author":"Hawser","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.ijid.2026.108826_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098000","article-title":"Epidemiology of extended-spectrum \u03b2-lactamase producing Escherichia coli in the stools of returning Japanese travelers, and the risk factors for colonization","volume":"9","author":"Yaita","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2026.108826_bib0007","unstructured":"National Antimicrobial Resistant Surveillance Center T. Antibiogram National Antimicrobial Resistance Surveillance Report 2024. Available from: https:\/\/narst.dmsc.moph.go.th\/antibiogram. Accessed March 1, 2026"},{"issue":"1","key":"10.1016\/j.ijid.2026.108826_bib0008","first-page":"478","article-title":"The Management of Menopausal symptoms","volume":"47","author":"Kamdaeng","year":"2020","journal-title":"Obstetr Gynecol"},{"key":"10.1016\/j.ijid.2026.108826_bib0009","unstructured":"Ayan Sabih S.W.L. Complicated urinary tract Infections National Library of Medicine: starpearls; 2024. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28613784\/."},{"key":"10.1016\/j.ijid.2026.108826_bib0010","article-title":"Experience with fosfomycin in the treatment of complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"6","author":"Bielen","year":"2019","journal-title":"Therap Adv Infect Dis"},{"key":"10.1016\/j.ijid.2026.108826_bib0011","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"22","key":"10.1016\/j.ijid.2026.108826_bib0012","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.12968\/bjon.1998.7.22.5533","article-title":"IV-related phlebitis, complications and length of hospital stay: 2","volume":"7","author":"Campbell","year":"1998","journal-title":"Br J Nurs"},{"key":"10.1016\/j.ijid.2026.108826_bib0013","first-page":"ciaf460","article-title":"Clinical practice guideline by Infectious Diseases Society of America (IDSA): 2025 guideline on management and treatment of complicated urinary tract infections: selection of antibiotic therapy for complicated UTI","author":"Trautner","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.ijid.2026.108826_bib0014","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1179\/joc.2010.22.5.355","article-title":"Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection","volume":"22","author":"Senol","year":"2010","journal-title":"J Chemother"},{"issue":"1","key":"10.1016\/j.ijid.2026.108826_bib0015","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijantimicag.2016.04.014","article-title":"Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum \u03b2-lactamase urinary tract infections","volume":"48","author":"Veve","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2026.108826_bib0016","series-title":"Fosfomycin vs ertapenem for outpatient treatment of complicated urinary tract infections: a multicenter, retrospective cohort study. Open forum infectious diseases","author":"Wald-Dickler","year":"2022"},{"key":"10.1016\/j.ijid.2026.108826_bib0017","doi-asserted-by":"crossref","unstructured":"Seo J-W, Yoon Y., Lyu Y.S., Na Y.S., Moon D.S., Yun N.R., et al., editors. Effect of oral fosfomycin compared to the intravenous beta lactam\/beta-lactamase inhibitor or carbapenem in step-down treatment of patients with complicated urinary tract infection due to extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae: a multicenter, open-label, randomized controlled, non-inferiority trial. Open Forum Infectious diseases; 2023.","DOI":"10.1093\/ofid\/ofad500.002"},{"issue":"3","key":"10.1016\/j.ijid.2026.108826_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01982-19","article-title":"Oral fosfomycin efficacy with variable urinary exposures following single and multiple doses against enterobacterales: the importance of heteroresistance for growth outcome","volume":"64","author":"Abbott","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"sup1","key":"10.1016\/j.ijid.2026.108826_bib0019","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/1120009X.2017.1380357","article-title":"Pharmacological properties of oral antibiotics for the treatment of uncomplicated urinary tract infections","volume":"29","author":"Novelli","year":"2017","journal-title":"J Chemother"},{"issue":"1","key":"10.1016\/j.ijid.2026.108826_bib0020","article-title":"Intravenous fosfomycin: an assessment of its potential for use in the treatment of systemic infections in Canada","volume":"2018","author":"Zhanel","year":"2018","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"1","key":"10.1016\/j.ijid.2026.108826_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2019.07.020","article-title":"Early switching of antibiotic therapy from intravenous to oral using a combination of education, pocket-sized cards and switch advice: a practical intervention resulting in reduced length of hospital stay","volume":"55","author":"Mouwen","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.ijid.2026.108826_bib0022","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/jac\/dkr053","article-title":"Radical reduction of cephalosporin use at a tertiary hospital after educational antibiotic intervention during an outbreak of extended-spectrum \u03b2-lactamase-producing Klebsiella pneumoniae","volume":"66","author":"T\u00e4ngd\u00e9n","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.ijid.2026.108826_bib0023","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ijantimicag.2010.12.003","article-title":"In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to nemonoxacin, tigecycline, fosfomycin and other antimicrobial agents","volume":"37","author":"Hsu MengShuian","year":"2011","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"10.1016\/j.ijid.2026.108826_bib0024","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01572-17","article-title":"Structure and dynamics of FosA-mediated fosfomycin resistance in Klebsiella pneumoniae and Escherichia coli","volume":"61","author":"Klontz","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2026.108826_bib0025","unstructured":"Administration TG. Fosfomycin trometamol \u2013 Product information 2018. Available from: https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-fosfomycin-trometamol-180907-pi.pdf. Accessed March 1, 2026"},{"key":"10.1016\/j.ijid.2026.108826_bib0026","unstructured":"Committee AM. Fosfomycin. Information for prescribers 2023. Available from: https:\/\/www.rightdecisions.scot.nhs.uk\/media\/2387\/fosfomycin-prescriber-information-hospital-guidance-final.pdf."},{"issue":"6","key":"10.1016\/j.ijid.2026.108826_bib0027","first-page":"569","article-title":"The Modified Early Warning Score (MEWS): an instant physiological prognostic indicator of poor outcome in acute pancreatitis","volume":"15","author":"Suppiah","year":"2014","journal-title":"J Pancreas"},{"issue":"2","key":"10.1016\/j.ijid.2026.108826_bib0028","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/JU.0000000000000296","article-title":"Recurrent uncomplicated urinary tract infections in women: AUA\/CUA\/SUFU guideline","volume":"202","author":"Anger","year":"2019","journal-title":"The J Urol"},{"key":"10.1016\/j.ijid.2026.108826_bib0029","unstructured":"I.I. JSL. Performance Standards for antimicrobial susceptibility testing, Wayne, PA, USA 2025 35: Available from: https:\/\/clsi.org\/shop\/standards\/m100\/."},{"issue":"5","key":"10.1016\/j.ijid.2026.108826_bib0030","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ijid.2026.108826_bib0031","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000449422","article-title":"Assessment of fosfomycin for complicated or multidrug-resistant urinary tract infections: patient characteristics and outcomes","volume":"62","author":"Giancola","year":"2017","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijid.2026.108826_bib0032","first-page":"1","article-title":"Clinical efficacy of fosfomycin for the treatment of complicated lower tract and uncomplicated urinary tract infections","volume":"8","author":"Nagel","year":"2015","journal-title":"Int Arch Med"},{"issue":"11","key":"10.1016\/j.ijid.2026.108826_bib0033","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Bonomo RAJAa, chemotherapy. Carbapenems: past, present, and future","volume":"55","author":"Papp-Wallace","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.ijid.2026.108826_bib0034","article-title":"Prevalence of fosfomycin resistance among enterobacterales isolates in a Tertiary Care hospital from Turkey","volume":"4","author":"\u00c7ayc\u0131","year":"2022","journal-title":"Infect Dis Clin Microbiol"},{"issue":"5","key":"10.1016\/j.ijid.2026.108826_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106574","article-title":"Susceptibility and resistance to fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study","volume":"59","author":"Tutone","year":"2022","journal-title":"Int J Antimicrob Agents"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226004613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226004613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:58:21Z","timestamp":1791212301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226004613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"alternative-id":["S1201971226004613"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108826","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral fosfomycin after carbapenems as de-escalating therapy in complicated urinary tract infections: A randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108826"}}